CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that it has received FDA 510(k) approval for six new hand piece configurations that expand its J-Plasma® pistol grip portfolio.
The pistol grip hand piece will now be available with instrument lengths of 15cm, 33cm and 45cm, in addition to the existing length of 27cm. Also, these new length hand pieces will each be available with a new needle configuration, as well as the standard blade configuration.
The new configurations have received FDA 510(k) approval and will be available beginning September 2015.
“In commercializing J-Plasma®, we have implemented a voice of customer initiative that resulted in new designs to respond to specific surgical needs,” said Robert L. Gershon, Chief Executive Officer. “The new lengths of our pistol grip hand pieces offer surgeons greater access and increases the opportunity for adoption across multiple specialties, while the new needle tip configuration provides even more precision resulting in less collateral damage to unintended tissue.”
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Forms 10-Q for the quarters ended June 30, 2015, and March 31, 2015 respectively. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.